Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
Thuốc Mosunetuzumab điều trị u lympho nang tái phát
Mosunetuzumab (LUNSUMIO®) [Acthera]
Mosunetuzumab Biosimilar Antibody (Recombinant CD20-CD3 Bispecific ...
FDA Approves Bispecific Antibody Mosunetuzumab for R/R Follicular Lymphoma
Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals ...
Phase I Trial of Mosunetuzumab Bispecific Antibody in
ASH 2021: Bispecific antibody mosunetuzumab brings deep remission for ...
Advantages of bispecific antibodies for lymphoma: mosunetuzumab ...
Mosunetuzumab Recombinant Human Monoclonal Antibody, Invitrogen 100 μg ...
Mosunetuzumab in R/R FL - Slideset Download - Hematology 2021 | CCO
Mosunetuzumab | 莫妥珠单抗 | TargetMol
Roche's Mosunetuzumab Approved for FL in China
Mosunetuzumab monotherapy is active and tolerable in patients with ...
FDA Approves Subcutaneous Mosunetuzumab in Follicular Lymphoma ...
Buy Mosunetuzumab Biosimilar - Anti-CD3E/MS4A1/CD20 mAb - Research ...
Mosunetuzumab – Application in Therapy and Current Clinical Research
Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma | CMAR
FDA Approves Subcutaneous Mosunetuzumab for R/R Follicular Lymphoma ...
Mosunetuzumab as a First-Time FL Treatment - HealthTree for Follicular ...
ASH 2021: Roche avduker data om sin nye immunterapi mosunetuzumab ...
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in ...
(PDF) Mosunetuzumab with polatuzumab vedotin in relapsed or refractory ...
Mosunetuzumab + Polatuzumab Vedotin for Aggressive B-Cell Lymphoma ...
Subcutaneous Mosunetuzumab Demonstrates Encouraging Efficacy ...
Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety ...
Figure 1 from Mosunetuzumab monotherapy is active and tolerable in ...
FDA批准首个用于R/R滤泡性淋巴瘤的双特异性抗体mosunetuzumab（Lunsumio）上市-MedSci.cn
ASH 2020: Dr. John Allan on Bispecific Antibodies for Chronic ...
CD20xCD3双抗梳理 近日，罗氏宣布FDA已接受其CD20xCD3双抗Mosunetuzumab（Lunsumio®）治疗非霍奇金淋巴瘤的 ...
双特异性T细胞衔接器（TCE）-CD3双抗-TCE作用机制/技术平台-德泰生物
ALL和NHL领域，临床开发中的双特异抗体|双特异抗体|临床|重链|药物|细胞|靶向|突变|-健康界
美国FDA批准mosunetuzumab获突破性药物资格，治疗滤泡性淋巴瘤(FL)-上市-医保-临床适应症-香港济民药业
罗氏“first-in-class”双特异性抗体疗法获美国FDA批准！
Full article: Trial watch: bispecific antibodies for the treatment of ...
The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From ...
记住所有FDA生物药 | 两款CD20 x CD3双抗 | Mosunetuzumab、Glofitamab | B细胞淋巴瘤 – 肖恩记药
Main T cell-redirecting bispecific antibodies in clinical development ...
Current Indications and Future Landscape of Bispecific Antibodies for ...
FDA Approves Lunsumio (mosunetuzumab-axgb) a First-in-Class Bispecific ...
双特异性抗体！罗氏公布mosunetuzumab、glofitamab、cevostamab强劲临床数据！ - 专区 - 生物谷
Frontiers | Immunotherapeutic progress and application of bispecific ...
Therapeutic potential of CD20/CD3 bispecific antibodies i...
T-cell-engaging bispecific antibodies in cancer - The Lancet
Frontiers | Current landscape and future directions of bispecific ...
Safety and efficacy of mosunetuzumab, a bispecific antibody, in ...
Lunsumio: A New Era In B-Cell Lymphoma Treatment
Bispecific Antibody Research Update: Epcoritamab Receives FDA Priority ...
FDA approves Roche’s Lunsumio VELO
Safety and Efficacy of Mosunetuzumab, A Bispecific Antibody, in ...
Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis ...
Single-Agent and Associated Therapies with Monoclonal Antibodies: What ...
全球首个CD20/CD3双抗获批上市 6月8日，罗氏宣布，欧盟委员会已授予CD20xCD3 T细胞结合双特异性抗体Lunsumio ...
莫妥珠单抗(Mosunetuzumab) - 药物靶点：CD20 x CD3_在研适应症：滤泡性淋巴瘤，侵袭性 B 细胞非霍奇金淋巴瘤，大B ...
Frontiers | T-cell redirecting therapies for B-cell non-Hodgkin ...
Treating & Managing NHL – NHL Strive
Lunsumio (Mosunetuzumab-axgb Injection): Side Effects, Uses, Dosage ...
(PDF) Mitigating the risk of cytokine release syndrome in a Phase I ...
How LUNSUMIO® (mosunetuzumab-axgb) is Thought to Work | HCP
Genentech | CD20/CD3双抗Mosunetuzumab获FDA授予优先审评资格
Impressive results of mosunetuzumab, a bispecific anti CD3/CD20 ...
LUNSUMIO (mosunetuzumab-axgb) injection - South Delhi Pharma
广州市皓博仪器仪表有限公司
CD20 X CD3双特异抗体格局 近日， Genmab 和艾伯维宣布其靶向CD20xCD3的双特异抗体epcoritamab（GEN3013 ...
Mitigating the risk of cytokine release syndrome in a Phase I trial of ...
Mosunetuzumab, a bispecific antibody, in patients with relapsed or ...
GSRS
记住所有FDA生物药 | 两款CD20 x CD3双抗 | Mosunetuzumab、Glofitamab | B细胞淋巴瘤 - 知乎
Presenting Mosunetuzumab: A Breakthrough in Lymphoma Treatment | Yeukai ...
Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to ...
Frontiers | Mechanisms of action of monoclonal antibodies in oncology ...
Systems‐based digital twins to help characterize clinical dose–response ...
记住所有FDA生物药 | 靶向CD20 x CD3双抗 | Epcoritamab | 弥漫性大B细胞淋巴瘤(DLBCL) - 知乎
Therapeutic potential of CD20 x CD3 bispecific antibodies - Omega ...
CD20之外，其余10个血液瘤双抗热门靶点 2022年6月8日，罗氏宣布Lunsumio® (mosunetuzumab)获得欧盟附加条件上市 ...
CD20xCD3双特异性抗体！罗氏glofitamab治疗侵袭性淋巴瘤(DLBCL)：完全缓解率39.4%! - 癌症研究专区 - 生物谷
Therapeutic potential of CD20/CD3 bispecific antibodies in the ...
Mosunetuzumab: effective and well-tolerated in the treatment of ...
Selected clinical trials that incorporate bispecific antibodies in ...
莫妥珠单抗 （mosunetuzumab）-LUNSUMIO说明书_药得
Mosunetuzumab: Uses, Interactions, Mechanism of Action | DrugBank
Bispecific Antibody - BiCell Scientific®
全球获批的10款双抗全梳理 近期，艾伯维/ Genmab 的CD3/CD20双抗获批上市，用于治疗复发难治性弥漫大B细胞淋巴瘤（R/R ...
mosunetuzumab-mosunetuzumab中文说明书,价格,哪里有卖-香港济民药业
罗氏为什么开发了两款成功的CD3xCD20双抗？ - 知乎
Lunsumio mosunetuzumab（莫妥珠单抗）副作用及注意事项_细胞_治疗_mg
复发或难治性滤泡型淋巴瘤首个双特异性抗体！Lunsumio(mosunetuzumab)获欧盟有条件批准 - 知乎
:%0A%0AMosunetuzumab%20+%20Polatuzumab%20Vedotin%20for%20Aggressive%20B-Cell%20Lymphoma.png?md=1)
